Infection control specialist now has its shares trading in Aim, the alternative investment market which is part of the London Stock Exchange.
Infection control specialist Tristel has successfully gained admission to trading on Aim, a market of the London Stock Exchange.
The company raised £2million and dealing in Tristel shares began on 1 June 2005.
Net proceeds receivable by the company are approximately £1.1million.
This will enable Tristel to increase its investment in sales and marketing for existing and new products, develop export markets, and increase its R and D to both enhance existing products and add new ones to its portfolio.
Tristel markets a proprietary chlorine dioxide chemistry that is highly effective in destroying all types of bacteria (including bacterial spores, tuberculosis and MRSA), fungi and viruses, and is, it says, one of a small group of sporicidal agents that is safe and easy to use.
Products in the Tristel range include solutions for medical instrument decontamination (primarily for flexible endoscopes), sporicidal wipes for non-lumened instruments, and the new Duo wipe system for the decontamination of hard surfaces.
A fully automated chlorine dioxide generator that allows the company's chemistry to be used in applications requiring continuous stream of chlorine dioxide, has also been added to the portfolio.
Paul Swinney, chief executive of Tristel, said: "Tristel is a growing business with patented technology.
"More than 60% of hospitals in the UK now use our products and we are helping to tackle the growing problem of hospital-acquired infection".
"By being admitted to trading on Aim and raising these funds, we can continue to grow into new areas and can further develop the high level of product support and the commitment to our customers for which we are known."
